Want to see CATX full AI Analyst Report?
Top Page
Perspective Therapeutics
(NYSE MKT:CATX)
Select Model
Select Model
Rating:53Neutral
Price Target:
$3.00
▲(3.09% Upside)
Action:Reiterated
Date:07/02/26
The score is held back primarily by very weak current financial performance (minimal revenue, large losses, and heavy cash burn). Technicals are mixed with negative MACD and price below longer-term moving averages. Offsetting these risks, the balance sheet is conservatively levered and recent corporate updates were positive, emphasizing clinical progress and manufacturing buildout.
Positive Factors
Conservative balance sheet
Extremely low leverage and substantial equity provide durable financial flexibility to fund multi-year clinical programs and manufacturing expansion. This reduces near-term refinancing risk, preserves optionality for partnerships or M&A, and supports execution over the next 2–6 months.
Negative Factors
High cash burn
Sustained negative operating and free cash flow indicates material cash consumption to advance trials and build manufacturing. Continued high burn increases funding needs, heightens dilution or financing risk, and constrains capital allocation if clinical timelines slip or costs rise.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Extremely low leverage and substantial equity provide durable financial flexibility to fund multi-year clinical programs and manufacturing expansion. This reduces near-term refinancing risk, preserves optionality for partnerships or M&A, and supports execution over the next 2–6 months.
Read all positive factors
Perspective Therapeutics (CATX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$331.87M
Dividend YieldN/A
Average Volume (3M)2.11M
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue Growth-57.99%
EPS Growth-15.44%
CountryUS
Employees166
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-26.44
Shares Outstanding114,046,196
10 Day Avg. Volume1,481,951
30 Day Avg. Volume2,113,515
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.33Price Target Upside358.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$374.10K
Perspective Therapeutics Business Overview & Revenue Model
Company Description
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solution...
How the Company Makes Money
null...
Perspective Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
78
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 618.00K | 0.00 | 1.45M | 1.43M | 7.10M | 10.79M |
| Gross Profit | -3.03M | 0.00 | -852.00K | 1.43M | 1.63M | 4.62M |
| EBITDA | -110.64M | -100.80M | 10.46M | -39.96M | -14.84M | -7.39M |
| Net Income | -111.13M | -103.12M | -79.28M | -46.51M | -14.67M | -7.15M |
Balance Sheet | ||||||
| Total Assets | 410.77M | 266.97M | 341.10M | 97.89M | 58.09M | 67.25M |
| Cash, Cash Equivalents and Short-Term Investments | 270.93M | 144.74M | 226.92M | 9.24M | 43.76M | 60.35M |
| Total Debt | 4.23M | 3.25M | 4.06M | 2.55M | 524.00K | 652.00K |
| Total Liabilities | 63.33M | 59.94M | 50.43M | 22.71M | 3.45M | 2.86M |
| Stockholders Equity | 347.44M | 207.03M | 290.67M | 75.18M | 54.64M | 64.39M |
Cash Flow | ||||||
| Free Cash Flow | -107.32M | -95.23M | -72.71M | -37.98M | -12.47M | -7.98M |
| Operating Cash Flow | -92.37M | -82.48M | -18.29M | -36.91M | -12.17M | -7.71M |
| Investing Cash Flow | -62.76M | 41.23M | -218.93M | 24.37M | -57.68M | -284.00K |
| Financing Cash Flow | 164.70M | 10.30M | 289.38M | 785.00K | 56.00K | 56.00K |
Perspective Therapeutics Technical Analysis
Negative
2.91
Price Trends
3.24
Negative
3.77
Negative
3.54
Negative
Market Momentum
-0.11
Positive
39.95
Neutral
28.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CATX, the sentiment is Negative. The current price of 2.91 is below the 20-day moving average (MA) of 3.05, below the 50-day MA of 3.24, and below the 200-day MA of 3.54, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 39.95 is Neutral, neither overbought nor oversold. The STOCH value of 28.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CATX.
Perspective Therapeutics Risk Analysis
Perspective Therapeutics disclosed 56 risk factors in its most recent earnings report. Perspective Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Perspective Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | $337.25M | 33.39 | 22.14% | ― | 16.79% | 45.17% | |
76 Outperform | $447.39M | 30.15 | 10.66% | ― | 23.10% | 22.75% | |
53 Neutral | $331.87M | -0.11 | -41.84% | ― | -57.99% | -15.44% | |
52 Neutral | $163.93M | -1.47 | -35.17% | ― | 6.85% | -90.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $278.83M | -3.22 | 162.57% | ― | 39.64% | -25.99% | |
46 Neutral | $68.20M | -0.86 | -51.88% | ― | 25.74% | -26.25% |
* Healthcare Sector Average
CATX
Perspective Therapeutics
2.91
-0.98
-25.19%
ELMD
Electromed
40.73
22.11
118.74%
QTRX
Quanterix
3.48
-2.56
-42.38%
VMD
Viemed Healthcare
11.67
5.60
92.26%
NNOX
Nano-X Imaging
0.98
-3.77
-79.39%
TLSI
TriSalus Life Sciences
4.54
0.34
8.10%
Perspective Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline
Positive
Jul 1, 2026
On July 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation to highlight progress on its 212Pb-based radiopharmaceutical pipeline and integrated manufacturing strategy. The company emphasized its theranostic approach, target...
Business Operations and StrategyProduct-Related Announcements
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline
Positive
Jun 1, 2026
On June 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation to highlight progress in its pipeline of 212Pb-based radiopharmaceuticals for solid tumors and to showcase its vertically integrated model for isotope production an...
Executive/Board ChangesShareholder Meetings
Perspective Therapeutics shareholders approve directors and governance items
Positive
May 27, 2026
On May 27, 2026, Perspective Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where 85.85% of the 114,017,755 outstanding common shares were represented, establishing a quorum for voting on board elections, auditor ratification, an...
Business Operations and Strategy
Perspective Therapeutics Showcases Strong Interim Radiopharma Data
Positive
May 22, 2026
On May 21, 2026, Perspective Therapeutics reported interim clinical data that will be presented at the 2026 ASCO Annual Meeting, highlighting consistent efficacy and safety profiles across all three of its radiopharmaceutical programs. Updated [21...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances
Positive
May 11, 2026
Perspective Therapeutics reported first-quarter 2026 results on May 11, 2026, highlighting progress across three clinical-stage oncology programs—VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma and PSV359 for FAP-positive solid ...
Business Operations and Strategy
Perspective Therapeutics Highlights Alpha-Targeted Oncology Strategy Update
Positive
May 4, 2026
On May 4, 2026, Perspective Therapeutics posted a new corporate presentation outlining its strategy to engineer an “alpha advantage” in targeted oncology using 212Pb-based radiopharmaceuticals. The materials highlight the company’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.